【摘要】 目的 观察长春瑞滨(Vinorelbine,商品名:盖诺)加奥沙利铂(Oxaliplatin,商品名:艾恒)联合化疗治疗晚期非小细胞肺癌(NSCLC)的临床效果和毒副反应。方法 26例晚期非小细胞肺癌患者采用盖诺25 mg/m2静脉推注,第1、8天;艾恒.130 mg/m2,静脉滴注4 h,第1天,21-28 d重复。结果 全组部分缓解(PR)9例,稳定(SD)12例,进展(PD)5例,总有效率(RR)为34.6％。主要毒副反应为骨髓抑制(Ⅲ-Ⅳ度白细胞减少发生率为42.3％)、神经毒性(80.8％)及恶心呕吐(42.3％)等。结论 长春瑞滨加奥沙利铂联合化疗方案治疗晚期非小细胞肺癌的疗效较高,耐受性好,值得临床进一步研究。更多还原

【Abstract】 Objective To evaluate the efficacy and safety of vinorelbine plus oxaliplatin in treatment of advanced non-small cell lung cancer (NSCLC) .Methods Twenty-six patients with NSCLC entered the study.The chemotherapy regimen consisted of vinorelbine 25 mg/m2 iv injection on days 1 and 8, oxaliplatin 130 mg/m2 iv infusion for 4 hours on day 1, repeated every 21-28 days. Results There were 9 partial response, 12 stable disease and 5 progression of disease, with the response rate being 34.6% . The major adverse effects were myelosuppression grade 3-4 occurring in 11 patients (42.3 % ) , neuro- sensory toxicity and vomiting observed in 80.8 % and 42.3 % of the patients respectively. Conclusions The vinorelbine plus oxaliplatin combined chemotherapy is an effective regimen for advanced non-small cell lung cancer with tolerable toxicity and deserves further evaluation.更多还原